YZYBIO-B News

YZYBIO-B: Articles of Association

Jun 27 19:40

YZYBIO-B: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON THURSDAY, JUNE 27, 2024

Jun 27 19:34

YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024

Jun 5 16:42

YZYBIO-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING OF 2023

May 29 22:00

YZYBIO-B: NOTICE OF THE ANNUAL GENERAL MEETING OF 2023

May 29 21:54

YZYBIO-B: CIRCULAR FOR THE ANNUAL GENERAL MEETING OF 2023

May 29 21:49

YZYBIO-B: PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

May 29 21:33

YZYBIO-B: PROPOSED ADOPTION OF THE 2024 H SHARE OPTION PLAN

May 29 21:28

YZYBIO-B: VOLUNTARY ANNOUNCEMENT - PHASE II STUDY DATA OF M701 FOR THE TREATMENT OFMALIGNANT ASCITES PRESENTED AT THE 2024 ASCO MEETING

May 24 16:30

YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

May 7 16:41

YZYBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Apr 30 17:37

YZYBIO-B: RESIGNATION OF NON-EXECUTIVE DIRECTOR

Apr 30 17:34

YZYBIO-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Apr 26 17:33

YZYBIO-B: 2023 ANNUAL REPORT

Apr 26 17:26

YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 5 17:04

YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2023

Mar 28 20:14

YZYBIO-B: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OFM701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANTASCITES

Mar 27 20:46

YZYBIO-B: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT ENROLLED IN PHASE II CLINICALTRIAL OF M701, A BISPECIFIC ANTIBODY FOR TREATMENT OFMALIGNANT PLEURAL EFFUSION

Mar 26 22:58

YZYBIO-B: Date of Board Meeting

Mar 15 16:35

YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 5 16:39